Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2023 Feb 6;19(2):e1010614. doi: 10.1371/journal.pgen.1010614

Differential modularity of the mammalian Engrailed 1 enhancer network directs sweat gland development

Daniel Aldea 1, Blerina Kokalari 1, Yuji Atsuta 2,¤, Heather L Dingwall 1, Ying Zheng 3, Arben Nace 3, George Cotsarelis 3, Yana G Kamberov 1,*
Editor: David R Beier4
PMCID: PMC9934363  PMID: 36745673

Abstract

Enhancers are context-specific regulators of expression that drive biological complexity and variation through the redeployment of conserved genes. An example of this is the enhancer-mediated control of Engrailed 1 (EN1), a pleiotropic gene whose expression is required for the formation of mammalian eccrine sweat glands. We previously identified the En1 candidate enhancer (ECE) 18 cis-regulatory element that has been highly and repeatedly derived on the human lineage to potentiate ectodermal EN1 and induce our species’ uniquely high eccrine gland density. Intriguingly, ECE18 quantitative activity is negligible outside of primates and ECE18 is not required for En1 regulation and eccrine gland formation in mice, raising the possibility that distinct enhancers have evolved to modulate the same trait. Here we report the identification of the ECE20 enhancer and show it has conserved functionality in mouse and human developing skin ectoderm. Unlike ECE18, knock-out of ECE20 in mice reduces ectodermal En1 and eccrine gland number. Notably, we find ECE20, but not ECE18, is also required for En1 expression in the embryonic mouse brain, demonstrating that ECE20 is a pleiotropic En1 enhancer. Finally, that ECE18 deletion does not potentiate the eccrine phenotype of ECE20 knock-out mice supports the secondary incorporation of ECE18 into the regulation of this trait in primates. Our findings reveal that the mammalian En1 regulatory machinery diversified to incorporate both shared and lineage-restricted enhancers to regulate the same phenotype, and also have implications for understanding the forces that shape the robustness and evolvability of developmental traits.

Author summary

Enhancers are regulatory elements in the genome that modulate the expression of protein-coding genes by directing how much, where, or when a given gene is expressed. Accordingly, enhancers are major determinants of mammalian traits and thought to be the predominant drivers of evolutionary change. Here we interrogated the identity and compared the functionality of the enhancers that control the specification of a single, highly variable trait, the density of sweat glands in mammalian skin, by regulating expression of the mammalian Engrailed 1 (En1) gene during development. We find that mammals have evolved two distinct types of enhancers to regulate this single trait: a shared enhancer active in multiple mammalian species that not only controls En1 expression in the skin but also in the brain, and also an enhancer whose activity is restricted to the skin of primates and rapidly evolved on this lineage to affect sweat phenotypes. Our findings implicate differences in the intrinsic properties of enhancers, namely the extent to which their activity is restricted to a specific context, in shaping not only the complexity of the regulatory landscape of a developmental gene but also the means by which that landscape evolves to generate trait variation.

Introduction

Eccrine sweat glands are specialized exocrine appendages of mammalian skin and are a major evolutionary innovation of this phylogenic class [1,2]. The main function of eccrine glands is to secrete hypotonic water onto the skin surface in response to specific neurological stimuli [2,3]. In the ancestral and most common state among mammals, eccrine glands develop only in the palmar/plantar (volar) skin of the ventral autopod (the distal-most segment of the limb) [13]. Here, eccrine glands are stimulated by cues from the limbic system and their secretions regulate frictional contact and grip [27]. In this context, eccrine glands are described as effectors of the fight or flight response, however, recent evidence also suggests that variation in volar eccrine glands is correlated with differential climbing ability in rodents [3,4,8,9]. Eccrine gland distribution has been expanded to nearly the entire body surface in humans and other catarrhine primates (the monkeys of Africa and Asia, and the anthropoid apes) [1,2,10]. Though structurally indistinguishable from their volar counterparts, generalized eccrine glands are activated by signals from the thermosensory regions of the hypothalamus and function in temperature regulation [2,3,1015]. The physiological importance of this regional expansion is paramount in humans, who have by far the greatest eccrine gland density of any primate [2,10,16], and who are reliant on the vaporization of eccrine sweat as the main means for cooling the body [2,3,5]. Given this extensive diversification, the study of how eccrine gland phenotypes evolved along mammalian lineages provides an exceptional inroad to understand the broader principles through which evolution generates natural variation and functional novelty.

The ability of any region of the skin to build eccrine glands relies on coordinated and reciprocal signaling between the deepest (basal) layer of the skin ectoderm from which eccrine glands arise and the underlying dermal mesenchyme [7,1721]. In both humans and mice, expression of the transcription factor Engrailed 1 (En1) in the basal ectoderm is a universal hallmark of all skin in which eccrine glands develop [17,22,23]. Moreover, the focal upregulation of En1 expression is the earliest, specific signature of eccrine gland placodes, thickenings of the ectoderm from which eccrine glands derive [17,22]. In mice, disruption of En1 expression in the basal ectoderm at the time of placode formation leads to dose-dependent decreases in the number of volar eccrine glands formed [2224]. Moreover, natural differences in volar eccrine gland number between inbred mouse strains are primarily the product of strain-specific variation in the quantitative levels of ectodermal En1 [22]. These findings illustrate the critical role of precise spatial, temporal, and quantitative regulation of the En1 locus in the generation of eccrine phenotypes.

For En1, as for the majority of protein coding loci, gene expression is coordinated by regulatory elements, or enhancers, that define where, when, and how much the En1 promoter is activated. Notably, En1 is essential for the development of multiple traits independent of its role in eccrine gland formation. These include patterning of the vertebrate midbrain/hindbrain, the formation of the cerebellum, and the dorso-ventral patterning of the embryonic limb bud [22,23,25,26]. Accordingly, control of En1 expression is likely to involve multiple enhancers that have, at least in part, non-overlapping, context-specific roles. Consistent with this, a recent study implicated a lncRNA-containing region distal to the En1 promoter in mice and humans that is required for En1 expression in the ectoderm during dorso-ventral limb patterning, but which is dispensable for En1 expression in the brain at the same stage [27]. Regulation of the En1 locus in the skin ectoderm is also subject to differential temporal control as evidenced by our finding that En1 upregulation in mouse strains with high eccrine gland density coincides with the period of placode formation in the volar ectoderm [22]. However, during earlier developmental stages, including during dorso-ventral patterning, the volar skin ectoderm of mouse strains with high and with low eccrine gland densities shows equivalent levels of En1 [22].

The importance of context-specific EN1 regulation to eccrine phenotypes is evident in our own species. Humans have the most dramatically derived eccrine phenotype of all mammals, having evolved an eccrine gland density that is on average ten times that of other catarrhines [2,10]. We recently uncovered that this adaptive elaboration is underlain by the evolution of an ectodermal EN1 enhancer, ECE18 (hg38 Chr2:118309555–118310531) [24]. The human homolog of ECE18 (hECE18) overlaps the human accelerated region (HAR) 2xHAR20, and has undergone rapid evolution on the human lineage [24,28,29]. Following the split from chimpanzees, successive mutation of the human ECE18 homolog (hECE18) has led to the accumulation of ten derived base substitutions that interact epistatically to render hECE18 the most quantitatively potent of all primate enhancer homologs [24]. Analysis of the endogenous capabilities of the hECE18 enhancer in human basal skin cells (keratinocytes) revealed that this element is required for EN1 expression in this context [24]. The ability of hECE18 to promote the formation of more eccrine glands by upregulating ectodermal En1 in a hECE18 mouse knock-in provided functional evidence that this element modifies EN1 expression to induce our species’ derived eccrine gland phenotype [24].

Intriguingly, the contribution of ECE18 to ectodermal EN1 regulation appears to be restricted to primates. Quantitative comparisons in mouse and human keratinocytes revealed that ECE18 homologs of species outside of the primate order have little to no enhancer activity [24]. Moreover, knock-out of the endogenous ECE18 enhancer in mice produces no effect on ectodermal En1 expression or on eccrine phenotypes in the volar skin of these animals [24]. Whether such species have evolved entirely different enhancers to modulate En1 in eccrine gland formation or there is differential redundancy in the activity of En1 enhancers in lineages outside of primates, is unclear. We therefore set out to determine if other enhancers have evolved to regulate ectodermal En1 expression in the context of eccrine gland development and to define their relationship to ECE18 in this respect.

Results

ECE20 is a developmental enhancer active in skin basal ectoderm

Using skin-specific, transgenic reporter mice, we have previously identified ECE20 (mm10 Chr1: 121176848–121178300) as a candidate En1 enhancer (ECE) in a screen for conserved, non-coding elements with enhancer activity in the basal ectoderm of eccrine forming skin (Figs 1A and S1A) [24]. ECE20 is located within the mapped human and mouse En1 topologically associated domains (TADs) as defined by High-C, approximately 500kb downstream of the En1 locus, and 79kb downstream of the ECE18 enhancer (Figs 1A, S1A and S1B) [24,30]. In contrast to ECE18, ECE20 does not show evidence of accelerated evolution in any mammalian clade [24,28,29].

Fig 1. ECE20 is a developmental enhancer active in basal ectoderm.

Fig 1

(A) Genomic locations of En1 candidate enhancers (ECEs) ECE18 and ECE20 (boxed) in the mouse genome (mm10). En1 Topological associating domain (TAD). (B) Strategy used to generate skin-specific transgenic mice to assess spatial and temporal activity of mouse ECE20 homolog (mECE20) in vivo. In situ hybridization for En1 mRNA (purple) in mouse volar limb skin at P2.5. Representative images of volar skin from the interfootpad (IFP) medial volar skin and footpad (FP) volar skin are shown. Nascent eccrine gland (black arrow). (C) Representative images of control and mECE20 transgenic P2.5 volar and dorsal limb autopods stained with anti-GFP antibody. eGFP is visualized using HRP-DAB-coupled immunohistochemistry so signal is brown. Nascent volar eccrine gland (black arrow). Dorsal hair follicle (head arrow). (D) Strategy to reconstitute transgenic human-derived developing ectoderm in hybrid human-mouse skin patches to test spatial and temporal activity of human ECE20 (hECE20) in vivo. (E) Representative images of a section from human developing skin infected with hECE20 or control virus and stained with antibody against GFP (brown) and also stained with the basal keratinocyte specific marker Keratin 14 (KRT14, Red). eGFP (black double head arrow) is visualized using HRP-DAB coupled immunohistochemistry so positive clones are brown. Primary human basal keratinocyte cells double positive for GFP and KRT14 (white double head arrow). DAPI nuclear stain (blue). See also S1 Fig.

Consistent with our published findings, the mouse homolog of ECE20 (mECE20) reproducibly induces eGFP reporter expression in the basal keratinocytes of the post-natal day (P) 2.5 mouse ventral autopod, recapitulating the pattern of endogenous En1 expression that is required at this stage for eccrine gland development (Fig 1B and 1C). In addition, mECE20 but not control transgenic mice have numerous GFP positive clones in the dorsal limb within the skin basal layer and also in the basal cells of the hair follicles that are present in this region (Fig 1C). This finding is significant in light of the expansion of EN1 expression to the developing basal ectoderm of the non-volar skin in species with generalized eccrine glands such as humans.

Assays to directly evaluate the enhancer activity of catarrhine ECE20 in a relevant context are not available since there are no in vitro models that recapitulate eccrine gland development. Moreover EN1 expression in the generalized basal skin ectoderm of such species begins late in gestation (~20 weeks gestation in humans), prohibiting direct interrogation of the ECE20 locus in situ [17]. Thus, to evaluate the potential of ECE20 as a developmental EN1 enhancer in the basal ectoderm of generalized skin, we turned to a heterotypic skin reconstitution assay in which primary human keratinocytes are directed to develop stratified epidermis and appendages by inductive developmental cues from mouse dermis (Fig 1D) [31]. To this end, primary human keratinocytes stably infected with lentivirus expressing an eGFP reporter cassette downstream of the human ECE20 (hECE20) enhancer (chr2: 118224252–118225644 [hg38])and minimal promoter, or with control eGFP virus, are mixed with inductive dermal cells from P0 mouse backskin and injected subcutaneously into the backs of nude mice [31]. In the resulting patches of humanized skin, the human-derived basal ectoderm becomes established, stratifies to form the superficial skin layers, and also gives rise to human keratinocyte-derived hair follicles, in accordance with the inductive potential of the underlying mouse dermis (Fig 1E) [31]. After 12 days, multiple eGFP positive clones are evident specifically in the basal, Keratin 14 (KRT14) positive, human keratinocytes of hECE20 infected patches, but not those infected with control virus (Fig 1E). Consistent with our observations in mECE20 transgenic mice, eGFP positive clones are also present in the human basal cells of the developing hair follicles (Fig 1E). This spatial pattern of activity is consistent with the pattern of EN1 expression in human developing skin, in which EN1 is expressed throughout the basal ectoderm including in the basal cells of fetal hair follicles. Notably, ECE20 homologs showed very weak or undetectable enhancer activity in cultured keratinocytes, suggesting that ECE20 enhancer activity is context-specific (S1C Fig). Our findings demonstrate that ECE20 homologs can function as enhancers in the Engrailed 1-expressing basal ectoderm during development, raising the possibility that ECE20 may be a conserved component of the endogenous machinery that modulates eccrine phenotypes in mammals.

ECE20 potentiates ectodermal En1 expression to induce the formation of eccrine glands

To determine whether mECE20 is an ectodermal En1 enhancer required for the development of eccrine glands we deleted the mECE20-containing genomic interval from the C57BL/6J mouse genome to create a mECE20 knock-out (mECE20KO) and analyzed En1 expression and eccrine phenotypes (Figs 2A and S2A). Homozygous mECE20KO mice are born at Mendelian ratios, are viable and fertile. Quantitative RT-PCR (qRT-PCR) analysis of En1 expression in P2.5 mouse volar skin reveals an average decrease of 20% in En1 mRNA in mECE20KO homozygotes as compared to wildtype (WT) sibling controls (Figs 2B and S2B). At this stage, the mouse volar skin is populated by eccrine gland anlagen at multiple stages of development, ranging from placodes in the central, inter-footpad (IFP) space to invaginating, nascent glands in the footpads (FPs) (Fig 1B) [22,32]. Comparison of the ratios of allelic En1 transcripts in the P2.5 volar skin of C57BL/6JWT: FVB/N as compared to C57BL/6JmECE20KO: FVB/N F1 hybrid mice shows that transcription is specifically downregulated at the En1 locus that has the ECE20KO allele in cis. (Figs 2C and S2C). Given this activity, we note that in silico motif analyses of human and mouse ECE20 homologs predict conserved biding sites for a number of transcription factors with enriched expression in the skin (S2D Fig). These data show that mECE20 is a bona fide En1 enhancer that upregulates ectodermal expression of this gene in the skin during eccrine gland development.

Fig 2. ECE20 potentiates En1 expression to induce the formation of eccrine glands.

Fig 2

(A) Strategy to generate mECE20 knock-out (mECE20KO) mouse. (B) Fold change in En1 mRNA by qRT-PCR in P2.5 volar hindlimb skin of wildtype (WT / WT), and mECE20KO homozygote (mECE20KO/ mECE20KO) mice relative to mean wildtype value. (C) Normalized En1 mRNA allelic ratio in volar hindlimb skin at P2.5 of wildtype (C57BL/6JWT / FVB/N) and mECE20KO (C57BL/6J(mECE20KO) / FVB/N) hybrid mice. Ratios reported are normalized to the genomic DNA allelic ratio. (D) Representative images of whole mount preparations of the volar hindlimb skin from WT / WT and mECE20KO/ mECE20KO adult mice. Epidermal preparations were stained to facilitate quantification of appendages in the interfootpad area (IFP, outlined in red dashed border). Insets show magnified views of regions within the IFP (black dashed border). Footpad (FP), eccrine gland (EG) and hair follicles (HF). (E) Quantification of IFP eccrine glands in the hindlimb volar skin of WT / WT and mECE20KO/ mECE20KO mice. (F) Quantification of IFP eccrine glands in En1KO / WT; WT / WT and En1KO / WT; WT / mECE20KO mice. In (B, C) each dot represents the mean value for an individual biological sample. In (E, F) each point represents the average number of eccrine glands in the IFP across both hindlimbs of a single mouse. In (B, C) mean (line) with standard deviation are plotted. In (E, F) the median (line) and maximum and minimum are reported for each genotype. In (B, C, E, F) significance assessed by a two-tailed T-test. ****P<0.0001, ** P<0.01. (KO) knock-out. In (B) Rlp13a was used as a housekeeping transcript for normalization. See also S2 Fig.

The importance of mECE20-dependent En1 upregulation is made evident in the volar skin of adult ECE20KO mice, who have on average 30% fewer eccrine glands in the IFP as compared to WT sibling controls (Figs 2D, 2E and S2E). Our previous studies implicating En1 in generating strain-specific variation in mouse volar eccrine gland density revealed that the IFP region and the eccrine glands that form therein are exceptionally sensitive to En1 levels [22]. Consistent with a mechanism in which ECE20 effects are mediated by the effect of this enhancer on En1, deletion of mECE20 potentiates the reduction in IFP eccrine glands in mice carrying one copy of the En1 knock-out allele (En1KO) (Figs 2F and S2F). These data implicate ECE20 as a conserved, developmental En1 enhancer necessary for the formation of eccrine sweat glands in the skin.

ECE20 has pleiotropic effects on En1 expression

mECE20 directly upregulates ectodermal En1 during eccrine gland development. Publicly available data from chromosome conformation capture (Capture C) analyses of the mouse embryonic limb bud and brain reveal that the genomic region containing mECE20 interacts with the En1 promoter in these tissues (S1A Fig) [33]. These findings raise the possibility that mECE20 may additionally regulate En1 in these contexts [23,25,26,34].

qRT-PCR analysis of normalized En1 mRNA expression in the ectoderm of embryonic day (E) 10.5 mouse limb buds reveals no significant difference between homozygous mECE20KO and WT sibling controls (Fig 3A and 3B). In line with this, we find no evidence of dorsalization in the limbs of mECE20KO mice. We also find no effect on the expression of ectodermal En1 in the E10.5 limb buds of mECE18KO mice (S3A Fig). Our findings reveal that despite the evidence of contact, mECE20 is not required for the activation of the En1 promoter in the limb ectoderm prior to the onset of eccrine gland formation in the region.

Fig 3. ECE20 has pleiotropic effects on En1 expression.

Fig 3

(A) Schematic of mouse embryonic day (E) 10.5 tissues harvested for quantitative analyses of En1 expression. (B) Fold change En1 mRNA assessed by qRT-PCR from autopods of wildtype (WT / WT), and mECE20KO homozygous (mECE20KO/ mECE20KO) mice at E10.5 relative to wildtype. (C) Fold change in En1 mRNA by qRT-PCR in midbrain-hindbrain tissue of wildtype (WT / WT), and mECE20KO homozygous (mECE20KO/ mECE20KO) mice compared to wildtype at E10.5. (D) Fold change in Fgf8, Fgf18 and Pax5 mRNA expression by qRT-PCR in midbrain-hindbrain tissue of wildtype (WT / WT), and mECE20KO homozygous (mECE20KO/ mECE20KO) mice compared to wildtype at E10.5. (E) Normalized En1 mRNA allelic ratio in midbrain-hindbrain of wildtype (C57BL/6JWT / FVB/N) and mECE20KO (C57BL/6J(mECE20KO) / FVB/N) hybrid mice. Ratios are normalized to the genomic DNA allelic ratio. In (B-E) each dot represents the mean value for an individual biological sample and the mean with standard deviation are plotted. In (B-E) significance assessed by a two-tailed T-test. ****P<0.0001, * P<0.05, n.s. not significant. (KO) knock-out. In (B, C) Rlp13a was used as a housekeeping transcript for normalization. See also S3 Fig.

In contrast to our findings in the embryonic limb, using qRT-PCR on dissected E10.5 mouse midbrain-hindbrain tissue, we find that normalized En1 mRNA levels are on average 50% lower in the mECE20KO homozygotes compared to WT sibling controls (Fig 3C). Allele-specific analyses of En1 transcripts in the E10.5 midbrain-hindbrains of C57BL/6JWT: FVB/N and C57BL/6JmECE20KO:FVB/N F1 hybrids show a mECE20KO-dependent skew in the En1 allelic ratio demonstrating that mECE20 is a cis acting regulatory element required to potentiate En1 transcription in this region (Fig 3D). The domain of En1 expression is unchanged in mECE20KOs relative to WT controls in this context, indicating that ECE20 regulates the levels rather than the pattern of En1 expression (S3B Fig). An in silico scan for predicted binding sites in ECE20 identifies conserved motifs for a number of brain-enriched transcription factors that may modulate the activity of the enhancer in this context (S3C Fig).

The magnitude of En1 reduction in the midbrain-hindbrains of ECE20KOs is sufficient to significantly decrease the transcription of Fgf8, Fgf18, and Pax 5, which are in a positive feedback circuit with En1 and critical for establishing and maintaining the regional identity of this brain region (Fig 3E) [3539]. In contrast to the significance of disrupting ECE20 on En1 and the developmental network that regionalizes the embryonic brain, we do not observe any change in the allelic expression of En1 in the midbrain-hindbrains of E10.5 hybrid mECE18KO animals (S3D Fig). Our data demonstrate that ECE20 has pleiotropic effects on En1 expression that are temporally and spatially constrained. Moreover, the contrasting functionalities of the murine homologs of ECE20 and ECE18 in this species give support to a model of differential usage of the two En1 enhancers in regulating the developmental expression of this gene during mammalian evolution.

ECE20 is not redundant with ECE18 in the regulation of mouse eccrine gland number

Studies suggest that multiple enhancers often act redundantly to provide robustness to developmental phenotypes [4042]. Our analyses of the ECE18 enhancer revealed that while this enhancer is required for endogenous EN1 expression in human basal keratinocytes, its activity is not required for ectodermal En1 activation in mice [24]. In light of the finding that mECE20 is part of the intrinsic En1 regulatory machinery in mice, we interrogated whether the absence of discernable eccrine phenotypes in the mECE18KO may be explained by functional redundancy with the mECE20 enhancer in the eccrine forming skin of this species. Accordingly, we used CRISPR-Cas9 genome editing of mECE20KO zygotes to generate a compound mECE18KO; mECE20KO mutant mouse model (Figs 4A and S4A).

Fig 4. ECE20 is not redundant with ECE18 in the regulation of mouse eccrine gland number.

Fig 4

(A) Strategy to generate mECE18; mECE20 (mECE18KO; mECE20KO) compound knock-out (KO) mouse. (B) Representative images of whole mount preparations of the volar hindlimb skin from mECE18WT/ mECE18WT; mECE20KO/ mECE20KO and mECE18KO/ mECE18KO; mECE20KO/ mECE20KO adult mice. Epidermal preparations were stained to facilitate quantification of appendages in the interfootpad area (IFP, outlined in red dashed border). Insets show magnified views of regions within the IFP (black dashed border). Footpad (FP), eccrine gland (EG) and hair follicles (HF). (C) Quantification of IFP eccrine glands in mECE18WT/ mECE18WT; mECE20KO/ mECE20KO and mECE18KO/ mECE18KO; mECE20KO/ mECE20KO mice. (D) Quantification of IFP eccrine glands in En1 KO / WT; WT / mECE20KO and En1 KO / WT; WT / mECE18KO; WT / ECE20KO mice. In (C, D) each point represents the average number of eccrine glands in the IFP across both hindlimbs of a mouse. In (C, D) significance assessed by a two-tailed T-test. n.s. not significant. (KO) knock-out. The median (line) and maximum and minimum are reported for each genotype. See also S4 Fig.

mECE18KO; mECE20KO compound homozygous mutant mice are born at Mendelian ratios, are viable and fertile. Comparative analyses of whole-mount epidermal preparations of volar skin reveal no additional reduction in IFP eccrine gland number in mice carrying compound deletions for mECE18 and mECE20 (mECE18KO; mECE20KO) as compared to mECE20KO alone on either a wildtype or in an En1-sensitized genetic background (Fig 4B–4D). These data demonstrate that mECE18 is not redundant with mECE20 in the generation of the mouse eccrine gland phenotype and reveal that the En1 regulatory machinery has diverged to incorporate both shared (ECE20) and lineage- specific (ECE18) modules that control the specification of eccrine gland density in the skin of mammals.

Discussion

Cis-regulatory modulation of the spatial, temporal, and quantitative expression of the Engrailed 1 locus is crucial to the formation of eccrine sweat glands in mammals [22,24]. Our findings in the mECE20KO mouse model, coupled with the pattern of mECE20 activity in transgenic mice, demonstrate that this enhancer is an essential factor controlling En1 expression in all of these dimensions. While we cannot directly determine the endogenous functional properties of the hECE20 ortholog in human development, the concordance in activity between hECE20 and mECE20 suggests that the role of ECE20 in regulating En1 is broadly conserved among divergent mammals. This is further supported by the high degree of sequence conservation between mouse and human ECE20 homologs, and contrasts with the accelerated divergence of the primate specific ECE18 enhancer [24,28]. In light of this evidence for ECE20 functional conservation and because En1 is the earliest-known factor that is exclusively required for the formation of eccrine glands, ECE20 ranks within the highest tier of the ancestral developmental cascade for making these appendages [17,22]. Future studies to identify the transcription factors that activate ECE20 will thus set the stage for elucidating the mediators that initiate the eccrine developmental program in the ectoderm.

An intriguing observation from our study is that the deletion of ECE20 results in a substantial but not a complete loss of En1 expression in the basal ectoderm. Consistent with our previous finding that eccrine gland number is dictated by En1 dosage, eccrine glands are significantly reduced but not entirely absent in mECE20KO animals. The buttressing of En1 expression against the loss of mECE20 may reflect the presence of additional En1 enhancers. Our results showing that both ECE18 and ECE20 human homologs are likely to regulate ectodermal EN1 during development are certainly consistent with such modular regulation of the locus in primates. Candidate regulatory elements that may provide these additional layers of mammalian En1 regulation include the ECE8 (Chr1: 120756823–120757766 [mm10]) and ECE23 (Chr1: 121394405–121395702 [mm10]) elements we have previously identified [24].

The results of our study not only implicate a multi-component network of enhancers that controls ectodermal En1 in mammalian eccrine gland phenotypes, but also highlight the functional compartmentalization of this network with respect to En1 regulation in distinct developmental contexts. A clear indication of this is the finding that mECE20 is required to potentiate En1 expression both in the embryonic brain and also in the skin during eccrine gland development, but not in the limb ectoderm during dorso-ventral patterning. The existence of a separable regulatory module for En1 expression in the latter context is supported by the identification of the Maenli lncRNA-containing region, deletion of which specifically results in a dorsalization phenotype in both human patients and in mice [27]. Studies of spatio-temporal differences in local chromatin configuration, particularly because of the proximity of En1 to the TAD boundary, and of the relative availability of transcription factors that regulate the respective enhancers are needed to determine why En1 engages with different enhancers in different contexts [43]. Considering the developmental importance of maintaining a ventral identity in the limb, it is intriguing to speculate that the evolution of independent modules for ectodermal En1 regulation in dorso-ventral patterning and in eccrine gland density specification could have facilitated the evolution of generalized eccrine glands in catarrhines.

Beyond its implications for the complexity of the En1 enhancer network, that ECE20 has pleiotropic effects on En1 expression not only in the skin but also in the brain, provides a potential explanation for the repeated targeting of the ECE18 enhancer during human evolution. Unlike ECE20, ECE18 activity appears to be restricted to the skin ectoderm. As such, our findings suggest that the potential for incurring deleterious exaptations in addition to the effects on eccrine gland density would be comparably lower from mutations in ECE18 than in ECE20. Future studies are needed to fully characterize the function of ECE20 in the brain, however the observed impact of ECE20 disruption on the EN1/FGF8 neural circuit required for maintaining the regional identities of the midbrain-hindbrain is consistent with such a model. By virtue of its context-specific function, the evolution of the primate ECE18 enhancer would allow catarrhines to generate eccrine gland phenotypic variation at a reduced risk of affecting the development and patterning of the brain. Thus, the pleiotropy of ECE20 coupled with the specificity of ECE18 could not only have favored but also constrained the evolution of catarrhine eccrine gland phenotypes to the ECE18 enhancer. Our findings not only implicate an underlying driver of modularity in ectodermal EN1 regulation, but also suggest a basis for the extreme derivation of hECE18 and its importance to the evolution of the singular eccrine phenotype of humans.

Materials and methods

Ethics statement

All research was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania Perelman School of Medicine under protocols 806105 and 805904.

Mice

CD1 (Crl:CD1) timed pregnant and FVB/NCrl mice were purchased from Charles River Laboratories. C57BL/6J mice were purchased from the Jackson Laboratories. En1KO mice were generated in the lab of Dr. Alexandra Joyner [26] and were obtained from the laboratory of Susan Dymecki (Harvard Medical School). En1KO mice were bred onto C57BL/6NTac (Taconic Biosciences) for at least 10 generations. Mice were housed in a vivarium on a 12h light/dark cycle. See also Table 1.

Table 1. Reagents and resources used in this study.

REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Chicken Polyclonal anti-GFP Abcam AB13970
Rabbit Polyclonal anti-Keratin 14 (Poly19053) Biolegend REF # 905303
Biotin-SP AffiniPure Rabbit Anti-Chicken IgY (IgG), Fc fragment specific Jackson ImmunoResearch REF # 303-065-008
Alexa Fluor 594 Jackson ImmunoResearch REF # 711-585-152
Anti-Digoxigenin-AP Fab fragments Roche REF # 11093274910
Bacterial and virus strains
Plasmid: lentiviral stagia GFP-reporter [24] N/A
Plasmid: mCherry (modified FUtdTW) Laboratory of Connie Cepko N/A
Plasmid: lentiviral bidirectional vector for luciferase assay [24] N/A
Chemically Competent E. coli Laboratory of Hao Wu Strain Stbl3
Biological samples
Primary human keratinocytes Core B of the Penn Skin Biology and Diseases and Resource-based Center N/A
Chemicals, peptides, and recombinant proteins
Polyethylenimine, Linear, MW 25000, Transfection Grade Polysciences, Inc REF # 23966–2
Nile Blue A Sigma-Aldrich N5632-25G
Oil Red O Sigma-Aldrich O0625-100G
DAPI (4’6-diamidino-2-phenylindole) Sigma-Aldrich REF # 10236276001
Keratinocyte serum-free medium (KSFM) ThermoFisher Scientific REF # 17005042
Epidermal growth factor (EGF), Human recombinant ThermoFisher Scientific REF # 10450–013
Bovine Pituitary Extract (BPE) ThermoFisher Scientific REF # 13028–014
Fetal bovine serum (FBS), Hyclone Fisher Scientific REF # SH3008003
Trypsin-EDTA (0.25%) ThermoFisher Scientific REF # 25200056
Penicillin-Streptomycin (10,000 U/mL) ThermoFisher Scientific REF # 15140122
DMEM—Dulbecco’s Modified Eagle Medium ThermoFisher Scientific REF # 11995065
Critical commercial assays
VECTASTAIN ELITE ABC Kit, Peroxidase Vector laboratories PK-6100
DAB Substrate Kit, Peroxidase (HRP) Vector laboratories SK-4100
Dual-Luciferase Reporter Assay System Promega E1910
RNeasy Mini Kit Qiagen REF # 74104
SuperScript III First-Strand Synthesis System ThermoFisher Scientific REF # 18080051
Ribonuclease H ThermoFisher Scientific REF # 18021014
RNase-Free DNase set Qiagen REF # 79254
PowerUP SYBR Green master mix ThermoFisher Scientific REF # A25742
NEBNext High-Fidelity 2X PCR Master Mix New England Biolabs REF # M0541S
DIG RNA Labeling Kit (SP6/T7) Roche REF # 11175025910
Experimental models: Cell lines
Human: GMA24F1A cell line Laboratory of Howard Green [51]
Human: HEK293T cell line Laboratory of Hao Wu N/A
Experimental models: Organisms/strains
Mouse: CD1/NCrl Charles River Laboratories N/A
Mouse: C57BL/6J The Jackson Laboratory Strain # 000664
Mouse: nu/nu nude mouse Charles River Laboratories N/A
Mouse: En1KO Laboratory of Susan Dymecki [26]
Mouse: mECE20KO This paper N/A
Mouse: mECE18KO; mECE20KO This paper N/A
Oligonucleotides
Primers for cloning, see S1 Table This paper N/A
Primers for qRT-PCR, see S1 Table [24] N/A
Primers for allelic discrimination assay, see S1 Table [22] N/A
Recombinant DNA
Plasmid: psPAX2 Laboratory of Didier Trono Addgene plasmid # 12260
Plasmid: pCL-VSV Laboratory of Connie Cepko N/A
Software and algorithms
GraphPad Prism version 9.41 for Windows Dotmatics https://www.graphpad.com/
QSVanalyzer software [52] http://dna-leeds.co.uk/qsv/
Guide Design Resources Feng Zhang lab http://crispr.mit.edu/
Other
Vevo-2100 Ultrasound FUJIFILM VisualSonics Inc. N/A
Leica DM5500B microscope Leica N/A
Leica DEC500 camera Leica N/A
The Applied Biosystems QuantStudio 7 Flex real-time PCR ThermoFisher Scientific REF # 4485701
Spectra Max i3x Molecular Devices https://www.moleculardevices.com/products/microplate-readers/multi-mode-readers/spectramax-i3x-readers

Generation of lentiviral-mediated transient transgenic mice

The mECE20 lentivirus mediated transgenic mice were generated as previously described [24,44]. Briefly, high-titer of lentiviral particles (mECE20 mixed with mCherry which allows the visualization of infected mice at harvest) were delivered into the amniotic cavity of embryonic day (E) 9 CD1/NCrl mouse embryos (Charles River Labs). Injections were performed under ultra-sound guidance using the Vevo 2100 ultrasound imaging system (Visualsonics, Toronto Canada) equipped with a 35–50 MHz mechanical transducer as described previously [24,44]. Primers used for cloning are reported in S1 Table. All survival surgeries were carried out in accordance with approved IACUC protocols. See also Table 1.

P 2.5 pups were sacrificed and both forelimbs, and both hindlimbs were harvested from mCherry positive animals. Limbs were processed by cryosection and immunohistochemical analysis was performed as described to detect GFP positive clones. See also Table 1.

Cell culture, transfection, and transduction

HEK293T cells were obtained from the laboratory of Dr. Hao Wu (University of Pennsylvania). Transfection of HEK293T cells was carried out using polyethylenimine (Polysciences Inc.). We used a second-generation packaging system to generate the lentiviruses used in this study (gift from Connie Cepko Harvard Medical School). All viruses were produced in HEK293T cells according to established protocols. Packaging plasmid psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260), envelope plasmid pCL-VSV was a gift from Connie Cepko (Harvard Medical School). See also Table 1.

Generation of hybrid human-mouse reconstituted skin

The enhancer activity of the hECE20 was tested in a humanized hybrid skin patch assay consisting of human derived epidermis coupled with mouse inductive dermis as described previously [31,45]. This system was previously shown to recapitulate the early stages of human skin development in vivo [45]. In brief, inductive mouse dermis was isolated from P0 CD1/NCrl mouse pups as previously described [45]. Primary human keratinocytes were isolated from human neonatal foreskin obtained from Core B of the Penn Skin Biology and Diseases and Resource-based Center. In brief, foreskin was incubated at 4°C for 12 hours in dispase II (2.4 U/ml). The epidermal sheet was separated from the underlying dermis and then transferred to a 60-mm tissue culture plate. Next, cells were incubated in 0.25% trypsin for 10 min at 37°C, and then neutralized with 1 ml of fetal bovine serum (FBS). Cell dissociation was carried out using mechanical force against sterile dish. The suspension was passed through a 40-μm strainer and then centrifuged at 200g for 5 min. The cell pellet was resuspended and plated in keratinocyte serum-free medium (SFM) supplemented with human recombinant epidermal growth factor (EGF) and bovine pituitary extract and 1% penicillin-streptomycin (10,000 U/ml) at 37°C. See also Table 1.

To generate hybrid cysts containing epidermis, dermis, and skin appendages, male nude (nu/nu) mice (Charles River) were anesthetized by isoflurane and injected with a mixture of transfected primary human keratinocytes and mouse dermal cells. A total of 2 x 106 cells (ratio 1:1) were resuspended in a final volume of 100 uL in DMEM (Invitrogen) and injected into the hypodermis of the mouse skin. The injection site was marked by a blue tattoo puncture. Hybrid skin cysts were harvested from mouse backskin 12 days later and fixed overnight in 4% Paraformaldehyde (PFA). Human derived cysts are easily distinguished by their subcutaneous location and nodular appearance. Only human keratinocytes are infected with GFP-expressing, replication incompetent lentivirus allowing for unambiguous distinction between human keratinocytes contributing to the developing epidermis and hair follicles in the cyst and any contaminating mouse keratinocyte cells, which do not have GFP. See also Table 1. Primers to clone hECE20 into the lentiviral vector are listed in S1 Table.

Primary human keratinocytes and HEK293T cells were maintained at 37°C under 5% CO2. GMA24F1A cells were maintained at 37°C under 10% CO2.

Genome alignments

Visualization of genome alignments and genomic annotations was generated by the UCSC Genome Browser (https://genome.ucsc.edu) [46].

in silico motif discovery analysis

DNA binding sites within ECE20 were identified using funMotifs (http://bioinf.icm.uu.se:3838/funmotifs/) with default parameters and the skin and brain datasets [47]. Evolutionary conserved motifs were filtered manually and motif calls were confirmed using the JASPAR 2022 database https://jaspar.genereg.net/ [48].

In situ hybridization, immunohistochemistry, and imaging

Tissues were embedded in OCT (Tissue Tek) and cryo-sectioned at a thickness of 10–12 μm. HRP (Horseradish peroxidase)/DAB(3,3-diaminobenzidine) immunostaining was performed as previously described [24]. Tissue was blocked in PBST (PBS + 0.1% Tween) + 10% normal donkey serum before incubating in chicken anti-GFP primary antibody (1:2000, Abcam). After washing, samples were incubated with biotin-SP-conjugated rabbit anti-chicken secondary antibody (1:250, Jackson ImmunoResearch). Samples were washed and incubated in Vectastain ABC reagent (Vector laboratories). Enzymatic detection was carried out using the DAB peroxidase substrate kit (Vector Laboratories) according to manufacturer’s instructions. Cytokeratin 14 primary antibody (CK14, 1:10000), Alexa Fluor594 (1:250, Jackson ImmunoResearch) and 4′6-diamidino-2-phenylindole (1:5000, Sigma Aldrich). Whole mount in situ hybridization of E10.5 mouse embryos was performed as previously described [49,50]. Briefly, embryos were fixed overnight at 4°C in 4% PFA. Next day, embryos were dehydrated through a methanol/PBST series. Single-stranded En1 anti-sense RNA probe was labeled with digoxigenin-UTP (Roche). After hybridization, the labeled RNA probe was detected with anti-digoxigenin-AP Fab fragments (Roche). See also Table 1. Images were acquired on a Leica DM5500B microscope equipped with a Leica DEC500 camera and on a Leica MZ12 stereomicroscope equipped with a Leica DFC295 camara for embryos pictures. See also Table 1.

Bidirectional luciferase vector and luciferase assays

Quantitative enhancer activity was assessed as previously described in human GMA24F1A human keratinocytes which express the basal keratinocyte marker KRT14 and also express EN1 [24,51]. Briefly, the mouse and human ECE20 orthologs were cloned upstream of a minimal tata-box promoter and upstream of the Firefly Luciferase reporter gene into the bidirectional luciferase lentiviral vector and using the primers listed in S1 Table. Lentivirus production and GMA24F1A human keratinocyte transduction was carried out as previously described [24]. Cells were harvested 72 hours post-transduction, and Firefly and Renilla (for normalization) Luciferase activities were measured using the Dual-luciferase reporter assay system (Promega). Luminescence was detected and quantified on the SpectraMax i3x (Molecular Devices). Experiments were carried out independently at least 3 times in biological triplicate each time. See also Table 1.

Generation and maintenance of ECE20 knock-out (mECE20KO) and of ECE18 and ECE20 compound knock-out (mECE18KO; mECE20KO) mice

For specific details of targeting design, strategy and validation, screening of founder animals and establishment of mutant lines see S2A (mECE20KO) and S4A Figs (mECE18KO; mECE20KO). In brief, pairs of guide RNAs (gRNAs) were designed using the online tool http://crispr.mit.edu/. Guides were tested to generate deletion of mouse ECE18 or ECE20 in vitro in NIH3T3 cells. The reported gRNAs which were confirmed to target mouse ECE18 or ECE20 in vitro were used to generate genome edited mice. gRNA selection, generation and in vitro testing were performed by the Perelman School of Medicine (PSOM) CRISPR Cas9 Mouse Targeting Core. Validated gRNAs along with Cas9 RNA were microinjected into the cytoplasm of C57BL/6J one cell embryos by the PSOM Mouse Transgenic and Chimeric mouse facility. Mouse ECE18 and ECE20 knock-out junctions were confirmed by Sanger sequencing. All procedures were performed in accordance with approved IACUC protocols. See also Table 1.

RNA extraction and quantitative RT-PCR

Total RNA extraction, cDNA synthesis and qRT-PCR were performed as previously described [24]. En1 total expression was determined as previously described and using the following primers S1 Table. Assays were performed in biological replicates consisting of at least three to four pooled, ventral fore or hindlimb skins at P2.5 or embryonic limb-buds at E10.5 from each genotype. Embryonic midbrain-hindbrain dissections were carried out by microdissection. cDNA was generated using SuperScript III (Thermo Fisher) according to the manufacturer’s instructions. qRT-PCR on each biological replicate was carried out using Power SYBR PCR master mix (Thermo Fisher) and each biological sample was analyzed in technical triplicate. Each data point reported in the manuscript represents the mean value for a biological replicate based on the technical triplicate for that sample. qRT-PCR values were normalized to Rpl13a. See also Table 1.

Allelic discrimination assay

En1 allelic expression assays were performed as previously described [22,24]. Briefly, ventral fore or hindlimb skin consisting of the region containing the five or six volar footpads and intervening IFP were dissected from P2.5 F1 C57BL/6J: FVB/N hybrid mice and RNA was extracted. For the embryonic tissue, limb-buds or mid-hindbrain were dissected at E10.5. Amplification of cDNA and gDNA products was done using the primers listed in S1 Table. En1 allelic expression was determined by the relative expression of C57BL/6J (mECE20KO) (mECE18KO; mECE20KO) vs. FVB/N allele as distinguished at rs3676156 [22,24]. Allelic expression data was analyzed using the sequencing based QSVanalyzer software [52]. Sequencing was carried out using the En1 Forward primer listed in S1 Table in technical triplicate for each sample. cDNA was obtained from biological replicates each consisting of three to four pooled, ventral fore or hindlimb skins, or three to four pooled, embryonic limb-buds, or the dissected midbrain-hindbrain regions of an individual mouse, for each genotype. Each data point reported in the manuscript represents the mean value for an individual biological sample. See also Table 1.

Quantification of eccrine glands

Quantification of mouse interfootpad (IFP) eccrine gland number was performed in whole-mount preparations of the volar skin epidermis of three to four week old euthanized mice as previously described [53]. Whole mount epidermal preparations were stained with Nile Blue (Sigma-Aldrich) and Oil Red O (Sigma-Aldrich) to visualize volar skin appendages (hair follicles and eccrine glands) and hair follicle-associated sebaceous glands, respectively. Every datapoint reported in the manuscript represents the average number of IFP eccrine glands in the left and right volar skin of an individual mouse. See also Table 1.

Statistical analysis

Statistical analysis was performed by means of student’s unpaired T-test (two-tailed) using GraphPad Prism version 9.41 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. See also Table 1.

Supporting information

S1 Fig. Features of the ECE20-containing genomic interval and activity of the ECE20 enhancer in cultured skin cells.

(A) Relative genomic position of Engrailed 1 candidate enhancer (ECE) 20 (boxed) and features of the ECE20-containing topologically associated domain (TAD, solid gray rectangle). Genomic positions of additional positive ECEs (red vertical lines) previously reported in Aldea et al. 2021 [24]. PhastCons scores based on alignment of placental mammals are depicted in green [46]. Called peaks from mouse embryonic limb and midbrain for interaction between the En1 promoter (anchor) and the genomic region containing ECE20 based on Capture-C (black, horizontal line), for CTCF enrichment (red and blue triangles show site location and directionality of CTCF sites), and for RAD21 enrichment (blue vertical lines) [33]. (B) Sequence alignment of mammalian genomes centered on ECE20 using mouse genome build mm10 as the base genome [46]. PhastCons scores for each position in the alignment are shown in green. Alignment and PhastCons scores are pulled from the USCS Genome browser (http://genome.ucsc.edu) [46] (C) Quantitative activity of mouse and human ECE20 orthologs in human GMA24F1A cultured keratinocytes, an immortalized human skin cell line that endogenously expressed EN1 [24,51,54]. The fold change in normalized luciferase activity relative to Control (empty vector) is plotted. Each dot represents a biological replicate. In (C) significance is assessed by one-way ANOVA and Tukey-adjusted P-values are reported. ***P<0.001, n.s. not significant.

(TIF)

S2 Fig. Functional characterization of the ECE20 enhancer in ectodermal En1 regulation and eccrine phenotypes.

(A) Generation of an ECE20 knock-out mouse (mECE20KO) by CRISPR-Cas9 mediated genome editing. CRISPR-Cas9 target sequence and genotyping strategy are shown. Deletion junctions were confirmed by Sanger sequencing of F1 pups. (B) Fold change in En1 mRNA by qRT-PCR in P2.5 volar forelimb skin of wildtype (WT / WT), and mECE20KO homozygote (mECE20KO/ mECE20KO) mice relative to wildtype. (C) Normalized En1 mRNA allelic ratio in volar forelimb of wildtype at P2.5 of wildtype (C57BL/6JWT / FVB/N) and mECE20KO (C57BL/6J(mECE20KO) / FVB/N) hybrid mice. Ratios were normalized to the allelic ratio in F1 genomic DNA. Each point represents the mean value across three technical replicates of biological samples consisting of pooled P2.5 volar skins from both forelimbs of two or three mice. (D) Location and identity of in silico-predicted DNA binding motifs for transcription factors enriched in skin that are evolutionarily conserved between mouse and human ECE20. Relative expression of the cognate transcription factor (TF expression) and motif score (TF score) are shown. Motifs identified using funMotifs (tissue-specific functional motifs) [47]. (E) Quantification of interfootpad (IFP) eccrine gland number in adult volar forelimbs of WT / WT and mECE20KO/ mECE20KO mice. (F) Quantification of IFP eccrine glands in adult, volar forelimbs of En1 KO / WT; WT / WT and En1 KO / WT; WT / mECE20KO mice. In (B, C) dots represent an individual biological replicate. In (E, F) each point represents the average number of eccrine glands in the IFP across both forelimbs of a mouse. In (B, C) mean (line) with standard deviation are plotted. In (E, F) the median (line) and maximum and minimum are reported for each genotype. In (B, C, E, F) significance assessed by a two-tailed T-test. ***P<0.001, ** P<0.01, * P<0.05. (KO) knock-out. In (B, C) Rlp13a was used as housekeeping transcript for normalization.

(TIF)

S3 Fig. Characterization of ECE20 and ECE18 in the mouse embryonic midbrain-hindbrain and limb-bud.

(A) Normalized En1 mRNA allelic ratios in forelimb autopods of wildtype (C57BL/6JWT / FVB/N) and mECE18KO (C57BL/6JmECE18KO / FVB/N) hybrid mice are plotted. (B) Whole-mount in situ hybridization for En1 in wildtype (WT / WT) and mECE20KO/ mECE20KO mice at E10.5. (C) Location and identity of in silico-predicted DNA binding motifs for transcription factors enriched in the brain that are evolutionarily conserved between mouse and human ECE20. Relative expression of the cognate transcription factor (TF expression) and motif score (TF score) are shown. Motifs identified using funMotifs (tissue-specific functional motifs) [47]. (C) Normalized En1 mRNA allelic ratios in midbrain-hindbrain of wildtype (C57BL/6JWT / FVB/N) and mECE18KO (C57BL/6JmECE18KO / FVB/N) hybrid mice. In (A, D) ratios are normalized to the allelic ratio in genomic DNA, and each point represents the mean value across three technical replicates of a pool of three or four mice for embryonic limb-bud in (A), or individual dissections of midbrain-hindbrain in (D) at E10.5. In (A, D) the mean (line) and the standard deviation are reported. In (A, D) significance assessed by a two-tailed T-test. n.s. not significant. (KO) knock-out.

(TIF)

S4 Fig. Generation of ECE18; ECE20 compound knock-out mice.

(A) Generation of an ECE18; ECE20 compound knock-out mouse (mECE18KO; mECE20KO) by CRISPR-Cas9 mediated genome editing. CRISPR-Cas9 target sequence and genotyping strategy are shown. Deletion junctions were confirmed by Sanger sequencing of F1 pups. (KO) knock-out.

(TIF)

S1 Table. Primers used to subclone ECE20 orthologs in mouse transgenic assays.

(DOCX)

S1 Data. Raw data main figures.

(XLSX)

S2 Data. Raw data S1S4 Figs.

(XLSX)

Acknowledgments

We thank Eric Joyce, Iain Mathieson, Pantelis Rompolas, Paola Kuri, Sixia Huang, and Gabriella Rice for helpful discussions on this project and on the manuscript. We thank Constance Cepko and Clifford J. Tabin for training, technical assistance, and support on ultrasound-guided injection.

Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NSF. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Data Availability

All data are available in the manuscript or the supplementary materials.

Funding Statement

Funding for this study was supported by award P30-DK19525 (https://www.nih.gov/) to the University of Pennsylvania Diabetes Research Center for the use of the Transgenic and Chimeric Mouse Facility Core to support work in this study, by award P30-AR069589 (https://www.nih.gov/) to the Penn Skin Biology and Diseases Resource-based Center (SBDRC) Cores A and B to support the work in this study, by award 5T32AR007465 (https://www.nih.gov/), which provided salary support to H. L. D., by awards BCS-1847598 (https://www.nsf.gov/) and R01AR077690 (https://www.nih.gov/) Y.G.K., which both provided salary support to Y.G.K. and funds for the work in this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Montagna W. Cutaneous Comparative Biology. Archives of Dermatology. 1971;104: 577–591. doi: 10.1001/archderm.1971.04000240001001 [DOI] [PubMed] [Google Scholar]
  • 2.Montagna W. Phylogenetic Significance of the Skin of Man. Arch Dermatol. 1963;88: 1–19. doi: 10.1001/archderm.1963.01590190007001 [DOI] [PubMed] [Google Scholar]
  • 3.Kuno Y. Human perspiration. Springfield, IL: Thomas; 1956. [Google Scholar]
  • 4.Adelman S, Taylor CR, Heglund NC. Sweating on paws and palms: what is its function? Am J Physiol. 1975;229: 1400–1402. doi: 10.1152/ajplegacy.1975.229.5.1400 [DOI] [PubMed] [Google Scholar]
  • 5.Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol. 1989;20: 537–563. doi: 10.1016/s0190-9622(89)70063-3 [DOI] [PubMed] [Google Scholar]
  • 6.Dobson RL, Sato K. The Secretion of Salt and Water by the Eccrine Sweat Gland. Archives of Dermatology. 1972;105: 366–370. doi: 10.1001/archderm.1972.01620060008002 [DOI] [PubMed] [Google Scholar]
  • 7.Cui C-Y, Schlessinger D. Eccrine sweat gland development and sweat secretion. Experimental dermatology. 2015;24: 644. doi: 10.1111/exd.12773 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Baker LB. Physiology of sweat gland function: The roles of sweating and sweat composition in human health. Temperature (Austin). 2019;6: 211–259. doi: 10.1080/23328940.2019.1632145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lissner J. Assessment of Foot Morphology in Peromyscus Related to Climbing Ability with Special Emphasis on Volar Pads. Muhlenberg College; Available: https://jstor.org/stable/community.30532389 [Google Scholar]
  • 10.Kamberov YG, Guhan SM, DeMarchis A, Jiang J, Wright SS, Morgan BA, et al. Comparative evidence for the independent evolution of hair and sweat gland traits in primates. J Hum Evol. 2018;125: 99–105. doi: 10.1016/j.jhevol.2018.10.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Montagna W. The Skin of Nonhuman Primates. American Zoologist. 1972;12: 109–124. [Google Scholar]
  • 12.Elizondo RS. Temperature regulation in primates. International Review of Physiology. 1977;15: 71–118. [PubMed] [Google Scholar]
  • 13.Whitford W. Sweating responses in the chimpanzee (Pan troglodytes). Comparative Biochemistry and Physiology Part A: Physiology. 1976;53: 333–336. doi: 10.1016/s0300-9629(76)80151-x [DOI] [PubMed] [Google Scholar]
  • 14.Elizondo RS. Primate models to study eccrine sweating. Am J Primatol. 1988;14: 265–276. doi: 10.1002/ajp.1350140307 [DOI] [PubMed] [Google Scholar]
  • 15.Best A, Kamilar JM. The evolution of eccrine sweat glands in human and nonhuman primates. Journal of Human Evolution. 2018;117: 33–43. doi: 10.1016/j.jhevol.2017.12.003 [DOI] [PubMed] [Google Scholar]
  • 16.Montagna W. The evolution of human skin(?). Journal of Human Evolution. 1985;14: 3–22. doi: 10.1016/S0047-2484(85)80090-7 [DOI] [Google Scholar]
  • 17.Lu CP, Polak L, Keyes BE, Fuchs E. Spatiotemporal antagonism in mesenchymal-epithelial signaling in sweat versus hair fate decision. Science. 2016;354: aah6102. doi: 10.1126/science.aah6102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lu CP, Polak L, Rocha AS, Pasolli HA, Chen S-C, Sharma N, et al. Identification of Stem Cell Populations in Sweat Glands and Ducts: Roles in Homeostasis and Wound Repair. Cell. 2012;150: 136–150. doi: 10.1016/j.cell.2012.04.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lu C, Fuchs E. Sweat Gland Progenitors in Development, Homeostasis, and Wound Repair. Cold Spring Harbor Perspectives in Medicine. 2014;4: a015222–a015222. doi: 10.1101/cshperspect.a015222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Cui C-Y, Yin M, Sima J, Childress V, Michel M, Piao Y, et al. Involvement of Wnt, Eda and Shh at defined stages of sweat gland development. Development. 2014;141: 3752–3760. doi: 10.1242/dev.109231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Plikus M, Wang WP, Liu J, Wang X, Jiang T-X, Chuong C-M. Morpho-regulation of ectodermal organs: integument pathology and phenotypic variations in K14-Noggin engineered mice through modulation of bone morphogenic protein pathway. Am J Pathol. 2004;164: 1099–1114. doi: 10.1016/S0002-9440(10)63197-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kamberov YG, Karlsson EK, Kamberova GL, Lieberman DE, Sabeti PC, Morgan BA, et al. A genetic basis of variation in eccrine sweat gland and hair follicle density. Proc Natl Acad Sci USA. 2015;112: 9932–9937. doi: 10.1073/pnas.1511680112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Loomis CA, Harris E, Michaud J, Wurst W, Hanks M, Joyner AL. The mouse Engrailed-1 gene and ventral limb patterning. Nature. 1996;382: 360–363. doi: 10.1038/382360a0 [DOI] [PubMed] [Google Scholar]
  • 24.Aldea D, Atsuta Y, Kokalari B, Schaffner SF, Prasasya RD, Aharoni A, et al. Repeated mutation of a developmental enhancer contributed to human thermoregulatory evolution. PNAS. 2021;118. doi: 10.1073/pnas.2021722118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wurst W, Auerbach AB, Joyner AL. Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum. Development. 1994;120: 2065–2075. doi: 10.1242/dev.120.7.2065 [DOI] [PubMed] [Google Scholar]
  • 26.Kimmel RA, Turnbull DH, Blanquet V, Wurst W, Loomis CA, Joyner AL. Two lineage boundaries coordinate vertebrate apical ectodermal ridge formation. Genes Dev. 2000;14: 1377–1389. [PMC free article] [PubMed] [Google Scholar]
  • 27.Allou L, Balzano S, Magg A, Quinodoz M, Royer-Bertrand B, Schöpflin R, et al. Non-coding deletions identify Maenli lncRNA as a limb-specific En1 regulator. Nature. 2021;592: 93–98. doi: 10.1038/s41586-021-03208-9 [DOI] [PubMed] [Google Scholar]
  • 28.Pollard KS, Salama SR, King B, Kern AD, Dreszer T, Katzman S, et al. Forces Shaping the Fastest Evolving Regions in the Human Genome. PLOS Genetics. 2006;2: e168. doi: 10.1371/journal.pgen.0020168 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Prabhakar S, Visel A, Akiyama JA, Shoukry M, Lewis KD, Holt A, et al. Human-specific gain of function in a developmental enhancer. Science. 2008;321: 1346–1350. doi: 10.1126/science.1159974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological Domains in Mammalian Genomes Identified by Analysis of Chromatin Interactions. Nature. 2012;485: 376–380. doi: 10.1038/nature11082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zheng Y, Hsieh J-C, Escandon J, Cotsarelis G. Isolation of Mouse Hair Follicle Bulge Stem Cells and Their Functional Analysis in a Reconstitution Assay. Methods Mol Biol. 2016;1453: 57–69. doi: 10.1007/978-1-4939-3786-8_8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Taylor DK, Bubier JA, Silva KA, Sundberg JP. Development, Structure, and Keratin Expression in C57BL/6J Mouse Eccrine Glands. Vet Pathol. 2012;49: 146–154. doi: 10.1177/0300985811430511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Andrey G, Schöpflin R, Jerković I, Heinrich V, Ibrahim DM, Paliou C, et al. Characterization of hundreds of regulatory landscapes in developing limbs reveals two regimes of chromatin folding. Genome Res. 2017;27: 223–233. doi: 10.1101/gr.213066.116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Simon HH, Saueressig H, Wurst W, Goulding MD, O’Leary DD. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci. 2001;21: 3126–3134. doi: 10.1523/JNEUROSCI.21-09-03126.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chi CL, Martinez S, Wurst W, Martin GR. The isthmic organizer signal FGF8 is required for cell survival in the prospective midbrain and cerebellum. Development. 2003;130: 2633–2644. doi: 10.1242/dev.00487 [DOI] [PubMed] [Google Scholar]
  • 36.Liu A, Joyner AL. EN and GBX2 play essential roles downstream of FGF8 in patterning the mouse mid/hindbrain region. Development. 2001;128: 181–191. doi: 10.1242/dev.128.2.181 [DOI] [PubMed] [Google Scholar]
  • 37.Gemel J, Jacobsen C, MacArthur CA. Fibroblast growth factor-8 expression is regulated by intronic engrailed and Pbx1-binding sites. J Biol Chem. 1999;274: 6020–6026. doi: 10.1074/jbc.274.9.6020 [DOI] [PubMed] [Google Scholar]
  • 38.Liu A, Li JYH, Bromleigh C, Lao Z, Niswander LA, Joyner AL. FGF17b and FGF18 have different midbrain regulatory properties from FGF8b or activated FGF receptors. Development. 2003;130: 6175–6185. doi: 10.1242/dev.00845 [DOI] [PubMed] [Google Scholar]
  • 39.Harada H, Sato T, Nakamura H. Fgf8 signaling for development of the midbrain and hindbrain. Development, Growth & Differentiation. 2016;58: 437–445. doi: 10.1111/dgd.12293 [DOI] [PubMed] [Google Scholar]
  • 40.Frankel N, Davis GK, Vargas D, Wang S, Payre F, Stern DL. Phenotypic robustness conferred by apparently redundant transcriptional enhancers. Nature. 2010;466: 490–493. doi: 10.1038/nature09158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Osterwalder M, Barozzi I, Tissières V, Fukuda-Yuzawa Y, Mannion BJ, Afzal SY, et al. Enhancer redundancy provides phenotypic robustness in mammalian development. Nature. 2018;554: 239–243. doi: 10.1038/nature25461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Tsai A, Alves MR, Crocker J. Multi-enhancer transcriptional hubs confer phenotypic robustness. Arnosti DN, Tyler JK, DePace AH, Garcia H, editors. eLife. 2019;8: e45325. doi: 10.7554/eLife.45325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Luppino JM, Park DS, Nguyen SC, Lan Y, Xu Z, Yunker R, et al. Cohesin promotes stochastic domain intermingling to ensure proper regulation of boundary-proximal genes. Nat Genet. 2020;52: 840–848. doi: 10.1038/s41588-020-0647-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Beronja S, Livshits G, Williams S, Fuchs E. Rapid functional dissection of genetic networks via tissue-specific transduction and RNAi in mouse embryos. Nat Med. 2010;16: 821–827. doi: 10.1038/nm.2167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Zheng Y, Du X, Wang W, Boucher M, Parimoo S, Stenn K. Organogenesis from dissociated cells: generation of mature cycling hair follicles from skin-derived cells. J Invest Dermatol. 2005;124: 867–876. doi: 10.1111/j.0022-202X.2005.23716.x [DOI] [PubMed] [Google Scholar]
  • 46.Navarro Gonzalez J, Zweig AS, Speir ML, Schmelter D, Rosenbloom KR, Raney BJ, et al. The UCSC Genome Browser database: 2021 update. Nucleic Acids Research. 2021;49: D1046–D1057. doi: 10.1093/nar/gkaa1070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Umer HM, Smolinska-Garbulowska K, Marzouka N, Khaliq Z, Wadelius C, Komorowski J. funMotifs: Tissue-specific transcription factor motifs. bioRxiv; 2019. p. 683722. doi: 10.1101/683722 [DOI] [Google Scholar]
  • 48.Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50: D165–D173. doi: 10.1093/nar/gkab1113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Wei Q, Manley NR, Condie BG. Whole mount in situ hybridization of E8.5 to E11.5 mouse embryos. J Vis Exp. 2011; 2797. doi: 10.3791/2797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.McGlinn E, Mansfield JH. Detection of gene expression in mouse embryos and tissue sections. Methods Mol Biol. 2011;770: 259–292. doi: 10.1007/978-1-61779-210-6_10 [DOI] [PubMed] [Google Scholar]
  • 51.Mainguy G, Ernø H, Montesinos ML, Lesaffre B, Wurst W, Volovitch M, et al. Regulation of epidermal bullous pemphigoid antigen 1 (BPAG1) synthesis by homeoprotein transcription factors. J Invest Dermatol. 1999;113: 643–650. doi: 10.1046/j.1523-1747.1999.00703.x [DOI] [PubMed] [Google Scholar]
  • 52.Carr IM, Robinson JI, Dimitriou R, Markham AF, Morgan AW, Bonthron DT. Inferring relative proportions of DNA variants from sequencing electropherograms. Bioinformatics. 2009;25: 3244–3250. doi: 10.1093/bioinformatics/btp583 [DOI] [PubMed] [Google Scholar]
  • 53.Kamberov YG, Wang S, Tan J, Gerbault P, Wark A, Tan L, et al. Modeling recent human evolution in mice by expression of a selected EDAR variant. Cell. 2013;152: 691–702. doi: 10.1016/j.cell.2013.01.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Aldea D, Kokalari B, Luckhart C, Aharoni A, Albert PR, Kamberov YG. The Transcription Factor Deaf1 Modulates Engrailed-1 Expression to Regulate Skin Appendage Fate. J. Invest. Dermatol. Elsevier; 2019;139(11):2378–2381.e4 doi: 10.1016/j.jid.2019.05.007 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

David R Beier, Bret Payseur

9 Nov 2022

Dear Dr Kamberov,

Thank you very much for submitting your Research Article entitled 'Differential modularity of the mammalian Engrailed 1 enhancer network directs sweat gland development' to PLOS Genetics.

The manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review a revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

David R. Beier

Academic Editor

PLOS Genetics

Bret Payseur

Section Editor

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: In this well written paper, Yana Kamberov and co-workers investigate the functions of ECE20, a putative enhancer of the En1 gene. They show that mouse ECE20 drives transgenic reporter gene expression in vivo in volar skin that will develop eccrine glands, as well as in basal epidermis and hair follicles in this region. ECE20 is well conserved between mouse and humans. To interrogate the human ECE20 homolog, the authors generated a lentivirus expressing a reporter gene downstream of human ECE20 and used this to infect primary human keratinocytes. The infected keratinocytes were mixed with inductive dermal cells from mouse backskin and injected subcutaneously into nude mice. The resulting cysts expressed the reporter gene in human basal epidermal and hair follicle cells, which reflects the expression of EN1 In developing human skin. These data indicated that ECE20 is active in both mouse and human skin. To assay for its functional importance, the authors deleted ECE20 in mice using gene editing. This caused reduced levels of En1 expression in volar skin and reduced numbers of sweat glands. Interestingly, En1 transcript levels were also reduced in E10.5 midbrain-hindbrain tissue, but not in E10.5 limb buds, where En1 is also expressed and directs dorso-ventral patterning. These data showed that ECE20 directs both tissue-restricted and temporally restricted En1 expression. The authors previously identified another En1 enhancer, ECE18, that is diverged from the mouse ECE18 sequence. ECE18 is required for En1 expression in human but not mouse skin. To test whether ECE20 and ECE18 function redundantly in mice, the authors generated mice lacking both enhancers. This did not result in a further reduction in En1 expression or eccrine sweat gland number beyond that seen with ECE20 deletion alone.

This paper addresses a very interesting question, namely how gene expression is controlled in a species, tissue and temporal specific fashion by distinct enhancer elements. The experiments were carried out in a logical and rigorous fashion with appropriate controls and statistical analyses. The data are clear and convincing, and will be of interest to a broad range of PLoS Genetics readers, including evolutionary biologists, and researchers interested in enhancer biology and in skin development.

I have several comments on the text; these should be addressed prior to publication to increase the impact of this study and broaden its potential audience:

1. The authors find that ECE20 deletion affects En1 levels in volar skin and in the midbrain-hindbrain region. In volar skin, this causes reduced numbers of eccrine sweat glands. Do the authors also observe abnormalities in the brain? These are predicted from their argument in the Discussion that ECE20 mutation would be detrimental to brain function and therefore selected against.

2. Do the authors observe predicted transcription motifs in ECE20 that are conserved between mouse and human, as would be expected given the apparently similar activity of ECE20 in the two species? Do these motifs differ from those seen in ECE18?

3. Along these lines, are there any transcription factors/transcription factor families predicted to bind conserved motifs in ECE20 that are expressed in the embryonic midbrain as well as in volar skin?

4. The legend for supplemental Figure S1 requires editing for the English.

Reviewer #2: Investigations into gene regulation guiding different tissue morphogenesis is an issue of great interest and complexity. This paper attempts to characterize a new enhancer involved in regulating the expression of engrailed 1 (EN1) that subsequently leads to different downstream consequences.

Engrailed is involved in specifying eccrine sweat glands in mammals and is also involved in patterning the vertebrate mid- and hindbrain of vertebrates and the dorsal-ventral embryonic limb bud. Authors explored candidate Engrailed enhancers. While in humans, ECE 18 has been shown to serve as an enhancer for Engrailed, it does not appear to serve this function in mice. Rather, ECE20, another enhancer identified on of their previous paper, seems to play this role in the mouse. Both ECE18 and ECE20 are found within the human mouse Engrailed topologically associated domain using High-C analysis. mECE20 can induce EGFP expression from a reporter construction appropriately in the mouse ventral autopod, reflecting normal Engrailed expression. A virally transduced hECE20 - eGFP reporter was introduced to human epithelium in a heterotypic skin reconstitution assay with mouse dermis when transplanted to the backs of nude mice. hECE20 can also induce expression eGFP expression in human skin basal keratinocytes in this assay. The ECE20KO studies convincing show the production of phenotypic changes in eccrine gland number. The combined En1KO/WT:WT/mECE20KO experiments further confirm the role of ECE20KO in regulating eccrine gland number. They then use the ECE18WT/mECE20KO experiments demonstrate that mECE18KO has no additional effects on endocrine gland number in mouse limbs. So, in the mouse, ECE20 plays this unique role. It is interesting the authors note that the inhibition by ECE20KO is not complete and other enhancers may also be involved in this regulation.

Enhancer study is an important question but is also complex. Here authors have developed new mice and use new functional approaches to assess the role of Engrailed enhancers. They have gain valuable new knowledges. The following can be clarified and discussed without new experiments.

1. Was High-C performed independently on the mouse dorsal limb and brain domains at P2.5 and P10.5? It is possible that these two regions temporal as well as regional differences in TAD configurations that might account for the differential response. Please clarify.

2. The viral enhancer-reporter constructs test human and mouse ECE20 function without regard to the TAD configuration. While it shows that human and mouse ECE20 are capable of regulating gene expression in the limb and skin, it doesn’t necessarily mean that they perform this function in their native state. Please discuss.

v

Minor

• ECE should be defined in abstract.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Decision Letter 1

David R Beier, Bret Payseur

13 Jan 2023

Dear Dr Kamberov,

We are pleased to inform you that your manuscript entitled "Differential modularity of the mammalian Engrailed 1 enhancer network directs sweat gland development" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

David R. Beier

Academic Editor

PLOS Genetics

Bret Payseur

Section Editor

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors have responded satisfactorily to my comments and this paper is now acceptable for publication in PLoS Genetics.

Reviewer #2: The revision is satisfactory for this reviewer.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-22-01084R1

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

David R Beier, Bret Payseur

1 Feb 2023

PGENETICS-D-22-01084R1

Differential modularity of the mammalian Engrailed 1 enhancer network directs sweat gland development

Dear Dr Kamberov,

We are pleased to inform you that your manuscript entitled "Differential modularity of the mammalian Engrailed 1 enhancer network directs sweat gland development" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Anita Estes

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Features of the ECE20-containing genomic interval and activity of the ECE20 enhancer in cultured skin cells.

    (A) Relative genomic position of Engrailed 1 candidate enhancer (ECE) 20 (boxed) and features of the ECE20-containing topologically associated domain (TAD, solid gray rectangle). Genomic positions of additional positive ECEs (red vertical lines) previously reported in Aldea et al. 2021 [24]. PhastCons scores based on alignment of placental mammals are depicted in green [46]. Called peaks from mouse embryonic limb and midbrain for interaction between the En1 promoter (anchor) and the genomic region containing ECE20 based on Capture-C (black, horizontal line), for CTCF enrichment (red and blue triangles show site location and directionality of CTCF sites), and for RAD21 enrichment (blue vertical lines) [33]. (B) Sequence alignment of mammalian genomes centered on ECE20 using mouse genome build mm10 as the base genome [46]. PhastCons scores for each position in the alignment are shown in green. Alignment and PhastCons scores are pulled from the USCS Genome browser (http://genome.ucsc.edu) [46] (C) Quantitative activity of mouse and human ECE20 orthologs in human GMA24F1A cultured keratinocytes, an immortalized human skin cell line that endogenously expressed EN1 [24,51,54]. The fold change in normalized luciferase activity relative to Control (empty vector) is plotted. Each dot represents a biological replicate. In (C) significance is assessed by one-way ANOVA and Tukey-adjusted P-values are reported. ***P<0.001, n.s. not significant.

    (TIF)

    S2 Fig. Functional characterization of the ECE20 enhancer in ectodermal En1 regulation and eccrine phenotypes.

    (A) Generation of an ECE20 knock-out mouse (mECE20KO) by CRISPR-Cas9 mediated genome editing. CRISPR-Cas9 target sequence and genotyping strategy are shown. Deletion junctions were confirmed by Sanger sequencing of F1 pups. (B) Fold change in En1 mRNA by qRT-PCR in P2.5 volar forelimb skin of wildtype (WT / WT), and mECE20KO homozygote (mECE20KO/ mECE20KO) mice relative to wildtype. (C) Normalized En1 mRNA allelic ratio in volar forelimb of wildtype at P2.5 of wildtype (C57BL/6JWT / FVB/N) and mECE20KO (C57BL/6J(mECE20KO) / FVB/N) hybrid mice. Ratios were normalized to the allelic ratio in F1 genomic DNA. Each point represents the mean value across three technical replicates of biological samples consisting of pooled P2.5 volar skins from both forelimbs of two or three mice. (D) Location and identity of in silico-predicted DNA binding motifs for transcription factors enriched in skin that are evolutionarily conserved between mouse and human ECE20. Relative expression of the cognate transcription factor (TF expression) and motif score (TF score) are shown. Motifs identified using funMotifs (tissue-specific functional motifs) [47]. (E) Quantification of interfootpad (IFP) eccrine gland number in adult volar forelimbs of WT / WT and mECE20KO/ mECE20KO mice. (F) Quantification of IFP eccrine glands in adult, volar forelimbs of En1 KO / WT; WT / WT and En1 KO / WT; WT / mECE20KO mice. In (B, C) dots represent an individual biological replicate. In (E, F) each point represents the average number of eccrine glands in the IFP across both forelimbs of a mouse. In (B, C) mean (line) with standard deviation are plotted. In (E, F) the median (line) and maximum and minimum are reported for each genotype. In (B, C, E, F) significance assessed by a two-tailed T-test. ***P<0.001, ** P<0.01, * P<0.05. (KO) knock-out. In (B, C) Rlp13a was used as housekeeping transcript for normalization.

    (TIF)

    S3 Fig. Characterization of ECE20 and ECE18 in the mouse embryonic midbrain-hindbrain and limb-bud.

    (A) Normalized En1 mRNA allelic ratios in forelimb autopods of wildtype (C57BL/6JWT / FVB/N) and mECE18KO (C57BL/6JmECE18KO / FVB/N) hybrid mice are plotted. (B) Whole-mount in situ hybridization for En1 in wildtype (WT / WT) and mECE20KO/ mECE20KO mice at E10.5. (C) Location and identity of in silico-predicted DNA binding motifs for transcription factors enriched in the brain that are evolutionarily conserved between mouse and human ECE20. Relative expression of the cognate transcription factor (TF expression) and motif score (TF score) are shown. Motifs identified using funMotifs (tissue-specific functional motifs) [47]. (C) Normalized En1 mRNA allelic ratios in midbrain-hindbrain of wildtype (C57BL/6JWT / FVB/N) and mECE18KO (C57BL/6JmECE18KO / FVB/N) hybrid mice. In (A, D) ratios are normalized to the allelic ratio in genomic DNA, and each point represents the mean value across three technical replicates of a pool of three or four mice for embryonic limb-bud in (A), or individual dissections of midbrain-hindbrain in (D) at E10.5. In (A, D) the mean (line) and the standard deviation are reported. In (A, D) significance assessed by a two-tailed T-test. n.s. not significant. (KO) knock-out.

    (TIF)

    S4 Fig. Generation of ECE18; ECE20 compound knock-out mice.

    (A) Generation of an ECE18; ECE20 compound knock-out mouse (mECE18KO; mECE20KO) by CRISPR-Cas9 mediated genome editing. CRISPR-Cas9 target sequence and genotyping strategy are shown. Deletion junctions were confirmed by Sanger sequencing of F1 pups. (KO) knock-out.

    (TIF)

    S1 Table. Primers used to subclone ECE20 orthologs in mouse transgenic assays.

    (DOCX)

    S1 Data. Raw data main figures.

    (XLSX)

    S2 Data. Raw data S1S4 Figs.

    (XLSX)

    Attachment

    Submitted filename: RESPONSE TO REVIEWERS.docx

    Data Availability Statement

    All data are available in the manuscript or the supplementary materials.


    Articles from PLOS Genetics are provided here courtesy of PLOS

    RESOURCES